← All trials
NCT06223919
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 16, 2023
- Primary completion
- Aug 22, 2024
- Completion date
- Dec 6, 2024
- First posted
- Jan 25, 2024
- Last posted
- Aug 16, 2024
- Enrollment
- 8686
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidad Nacional de ColombiaLead sponsor
- Government of JapanCollaborator
- National Center for Global Health and MedicineCollaborator
- Government of ColombiaCollaborator
- Universidad Nacional de ColombiaOfficial
- Japan Agency for Medical Research and DevelopmentCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.